Patent US5208233A successfully refreshed from Google Patents.
US5208233A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
Assignee: United States Department of Health and Human Services
•
Filing: 1991-08-12
•
Granted: 1993-05-04
•
Expires: 2011-08-12
Abstract
Abstract There are disclosed anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component in the anti-hypertensive compositions is a compound of the formula <IMAGE> wherein R1 and R2 are independently selected from straight chain and branched chain C1-C12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl group; or R1 and R2 together with the nitrogen atom they are bonded to form a heterocyclic ring; M+X is a pharmaceutically acceptable cation, wherein x is the valence of the cation.
Inventors
- 👤 Larry K. Keefer
- 👤 David A. Wink
- 👤 Tambra M. Dunams
- 👤 Joseph A. Hrabie
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 08:44
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/22; C07D295/28; C07D295/30; A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/395; A61K31/40; A61K31/435; A61K31/44; A61K31/445; A61K31/495; A61K31/535; C07C; C07C291/00; C07C291/02; C07C291/08; C07C307/00; C07C307/02
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
64 words
An injectable pharmaceutical composition comprising an effective amount of a compound of the Formula: ##STR9## wherein R 1 and R 2 together with the nitrogen atom are bonded to form a heterocyclic group of the Formula ##STR10## wherein Z is 1 to 5, M +X is a pharmaceutically acceptable cation, and x is the valence of the cation; and a pharmaceutically acceptable sterile carrier.
Claim 2
Dependent Claim
64 words
An injectable pharmaceutical composition comprising an effective amount of a compound of the Formula: ##STR9## wherein R 1 and R 2 together with the nitrogen atom are bonded to form a heterocyclic group of the Formula ##STR10## wherein Z is 1 to 5, M +X is a pharmaceutically acceptable cation, and x is the valence of the cation; and a pharmaceutically acceptable sterile carrier.
Claim 3
Dependent Claim
16 words
The composition of claim 1, wherein the Formula I compound is a bis(morpholino)bis (nitric oxide) adduct.
Claim 4
Dependent Claim
27 words
The composition of claim 1, wherein M +X is Na + , K + , Ca +2 or (R 1 )(R 2 ) NH 2 + .
Claim 5
Dependent Claim
34 words
The composition of claim 1, wherein R 1 and R 2 together with the nitrogen they are bonded to form a heterocyclic ring selected from the group consisting of: morpholino, 1-aza-12-crown-4, 1-aza-15-crown-5, and 1-aza-18-crown-6.
Claim 6
Independent Claim
86 words
A method of treating a cardiovascular disorder in a mammal in need of such treatment, the method comprising lowering the blood pressure of the mammal by administering to the mammal a blood pressure lowering effective amount of a compound of the formula: ##STR11## wherein R 1 and R 2 together with the nitrogen atom are bonded to form a heterocyclic ring of the formula ##STR12## wherein Z is 1 to 5, M +X is a pharmaceutically acceptable cation, and x is the valence of the cation.
Claim 7
Independent Claim
86 words
A method of treating a cardiovascular disorder in a mammal in need of such treatment, the method comprising lowering the blood pressure of the mammal by administering to the mammal a blood pressure lowering effective amount of a compound of the formula: ##STR11## wherein R 1 and R 2 together with the nitrogen atom are bonded to form a heterocyclic ring of the formula ##STR12## wherein Z is 1 to 5, M +X is a pharmaceutically acceptable cation, and x is the valence of the cation.
Claim 8
Dependent Claim
16 words
The method of claim 5, wherein the formula I compound is a bis(morpholino)bis (nitric oxide) adduct.
Claim 9
Dependent Claim
31 words
The method of claim 5, wherein the cardiovascular disorder treated is chronic hypertension, hypertensive crisis, acute congestive heart failure, angina, acute myocardial infarction, left ventricular failure, cerebrovascular insufficiency or intracranial hemorrhage.
Claim 10
Dependent Claim
34 words
The method of claim 5, wherein R 1 and R 2 together with the nitrogen they are bonded to form a heterocyclic ring selected from the group consisting of: morpholino, 1-aza-12-crown-4, 1-aza-15-crown-5, and 1-aza-18-crown-6.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-03 | 1996-11-02 | 1997-05-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-03 | 2000-11-02 | 2001-05-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-03 | 2004-11-02 | 2005-05-04 | $7700.00 | Window Closed / Lapsed |